{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:42:53Z","timestamp":1785368573153,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010763","name":"Zorginstituut Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Glioblastoma (GBM) is the most common primary, malignant brain tumour with a 5-year survival of 5%. If possible, a glioblastoma is resected and further treated with chemoradiation therapy (CRT), but resection is not feasible in about 30% of cases. Current standard of care in these cases is a biopsy followed by CRT. Magnetic resonance (MR) imaging-guided laser interstitial thermal therapy (LITT) has been suggested as a minimally invasive alternative when surgery is not feasible. However, high-quality evidence directly comparing LITT with standard of care is lacking, precluding any conclusions on (cost-)effectiveness. We therefore propose a multicenter randomized controlled study to assess the (cost-)effectiveness of MR-guided LITT as compared to current standard of care (EMITT trial).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and analysis<\/jats:title>\n                <jats:p>The EMITT trial will be a multicenter pragmatic randomized controlled trial in the Netherlands. Seven Dutch hospitals will participate in this study. In total 238 patients will be randomized with 1:1 allocation to receive either biopsy combined with same-session MR-guided LITT therapy followed by CRT or the current standard of care being biopsy followed by CRT. The primary outcomes will be health-related quality of life (HR-QoL) (non-inferiority) using EORTC QLQ-C30\u2009+\u2009BN20 scores at 5 months after randomization and overall survival (superiority). Secondary outcomes comprise cost-effectiveness (healthcare and societal perspective) and HR-QoL of life over an 18-month time horizon, progression free survival, tumour response, disease specific survival, longitudinal effects, effects on adjuvant treatment, ablation percentage and complication rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The EMITT trial will be the first RCT on the effectiveness of LITT in patients with glioblastoma as compared with current standard of care. Together with the Dutch Brain Tumour Patient association, we hypothesize that LITT may improve overall survival without substantially affecting patients\u2019 quality of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial is registered at ClinicalTrials.gov (NCT05318612).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-023-11282-7","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T10:03:03Z","timestamp":1692784983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial)"],"prefix":"10.1186","volume":"23","author":[{"given":"C\u00e9line L.G.","family":"Neutel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Viozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan G.","family":"Overduin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rijpma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke P.C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerjon","family":"Hannink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"van Eijsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre A.","family":"Robe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroeska M.","family":"Rovers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"ter Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"11282_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/B978-0-12-802997-8.00023-2","volume":"134","author":"HG Wirsching","year":"2016","unstructured":"Wirsching HG, Galanis E, Weller M, Glioblastoma. Handb Clin Neurol. 2016;134:381\u201397.","journal-title":"Handb Clin Neurol"},{"key":"11282_CR2","doi-asserted-by":"crossref","unstructured":"Grochans S, Cybulska AM, Simi\u0144ska D, Korbecki J, Kojder K, Chlubek D et al. Epidemiol Glioblastoma Multiforme-Literature Rev Cancers (Basel). 2022;14(10).","DOI":"10.3390\/cancers14102412"},{"issue":"1","key":"11282_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5\u201329.","journal-title":"CA Cancer J Clin"},{"key":"11282_CR4","unstructured":"IKNL. Incidentie hersentumoren 2020 [Available from: https:\/\/iknl.nl\/kankersoorten\/hersentumoren\/registratie\/incidentie."},{"issue":"10","key":"11282_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"9","key":"11282_CR6","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","volume":"15","author":"M Weller","year":"2014","unstructured":"Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395\u2013403.","journal-title":"Lancet Oncol"},{"issue":"11","key":"11282_CR7","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","volume":"2","author":"TJ Brown","year":"2016","unstructured":"Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, et al. Association of the extent of Resection with Survival in Glioblastoma: a systematic review and Meta-analysis. JAMA Oncol. 2016;2(11):1460\u20139.","journal-title":"JAMA Oncol"},{"key":"11282_CR8","doi-asserted-by":"crossref","unstructured":"Haj A, Doenitz C, Schebesch KM, Ehrensberger D, Hau P, Putnik K et al. Extent of resection in newly diagnosed glioblastoma: impact of a Specialized Neuro-Oncology Care Center. Brain Sci. 2017;8(1).","DOI":"10.3390\/brainsci8010005"},{"issue":"2","key":"11282_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-019-03229-5","volume":"144","author":"PC De Witt Hamer","year":"2019","unstructured":"De Witt Hamer PC, Ho VKY, Zwinderman AH, Ackermans L, Ardon H, Boomstra S, et al. Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro surgery. J Neurooncol. 2019;144(2):313\u201323.","journal-title":"J Neurooncol"},{"issue":"6C","key":"11282_CR10","first-page":"4605","volume":"25","author":"C NIEDER","year":"2005","unstructured":"NIEDER C, GROSU AL. Treatment of Unresectable Glioblastoma Multiforme. Anticancer Res. 2005;25(6\u00a0C):4605\u201310.","journal-title":"Anticancer Res"},{"key":"11282_CR11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.wneu.2018.01.123","volume":"112","author":"O Ashraf","year":"2018","unstructured":"Ashraf O, Patel NV, Hanft S, Danish SF. Laser-Induced Thermal Therapy in Neuro-Oncology: a review. World Neurosurg. 2018;112:166\u201377.","journal-title":"World Neurosurg"},{"key":"11282_CR12","doi-asserted-by":"crossref","unstructured":"Viozzi I, Guberinic A, Overduin CG, Rovers MM, Ter Laan M. Laser interstitial thermal therapy in patients with newly diagnosed glioblastoma: a systematic review. J Clin Med. 2021;10(2).","DOI":"10.3390\/jcm10020355"},{"key":"11282_CR13","doi-asserted-by":"crossref","unstructured":"Viozzi I, Overduin CG, Rijpma A, Rovers MM, ter Laan M. MR-guided LITT therapy in patients with primary irresectable glioblastoma: a prospective, controlled pilot study. JNO Date of acceptance: 10 Jun, 2023.","DOI":"10.1016\/j.bas.2022.101497"},{"issue":"4","key":"11282_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3171\/2015.7.JNS15244","volume":"125","author":"P Patel","year":"2016","unstructured":"Patel P, Patel NV, Danish SF. Intracranial MR-guided laser-induced thermal therapy: single-center experience with the visualase thermal therapy system. J Neurosurg. 2016;125(4):853\u201360.","journal-title":"J Neurosurg"},{"issue":"4","key":"11282_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","volume":"50","author":"M Groenvold","year":"1997","unstructured":"Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol. 1997;50(4):441\u201350.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"11282_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","volume":"46","author":"MJ Taphoorn","year":"2010","unstructured":"Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6):1033\u201340.","journal-title":"Eur J Cancer"},{"key":"11282_CR17","doi-asserted-by":"crossref","unstructured":"EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"11282_CR18","volume-title":"Manual iMTA Medical cost questionnaires (iMCQ)","author":"iMTA Productivity and Health Research Group","year":"2018","unstructured":"iMTA Productivity and Health Research Group. Manual iMTA Medical cost questionnaires (iMCQ). Rotterdam: iMTA, Erasmus University Rotterdam; 2018."},{"key":"11282_CR19","unstructured":"Manual of the iMTA. Productivity cost questionnaire (iPCQ). Rotterdam: iMTA, Erasmus University Rotterdam, 2018 iMTA Productivity and Health Research Group."},{"issue":"9","key":"11282_CR20","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdq726","volume":"22","author":"J Maringwa","year":"2011","unstructured":"Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol. 2011;22(9):2107\u201312.","journal-title":"Ann Oncol"},{"issue":"12","key":"11282_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(05)70432-0","volume":"6","author":"MJ Taphoorn","year":"2005","unstructured":"Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6(12):937\u201344.","journal-title":"Lancet Oncol"},{"issue":"45","key":"11282_CR22","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta11450","volume":"11","author":"R Garside","year":"2007","unstructured":"Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii\u2013iv. ix-221.","journal-title":"Health Technol Assess"},{"issue":"10","key":"11282_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0269216313486952","volume":"27","author":"NJ Preston","year":"2013","unstructured":"Preston NJ, Fayers P, Walters SJ, Pilling M, Grande GE, Short V, et al. Recommendations for managing missing data, attrition and response shift in palliative and end-of-life care research: part of the MORECare research method guidance on statistical issues. Palliat Med. 2013;27(10):899\u2013907.","journal-title":"Palliat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11282-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T07:09:24Z","timestamp":1700377764000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11282-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11282"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11282-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval has been granted by the Medical Ethical Committee region Arnhem-Nijmegen, the Netherlands on the 21st of March 2022 (NL79202.091.21). All methods will be carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the Medical Ethical Committee region Arnhem-Nijmegen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research ethics approval"}},{"value":"Informed consent will be obtained from all subjects and\/or their legal guardian(s).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The preliminary pilot study was co-financed by Medtronic. Medtronic has no financial contribution to the EMITT trial. MtL is a board member of the Dutch Society of Neuro Oncology. This organization advises the ministry on including certain treatments in the basic healthcare package and is responsible for drawing up treatment guidelines. All other authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Important protocol modifications will be resubmitted to the MEC and will be communicated to all investigators and trial participants as well as the DSMB and the Dutch Healthcare Institute.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Protocol amendments"}},{"value":"The results of the study will be disclosed unreservedly. Both positive and negative results will be submitted for publication to peer-reviewed journal. The results of the study will be presented at (inter)national meetings and will be shared with the patient association and study participants.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Dissemination policy"}},{"value":"This study is in the process of recruiting participants as of the 8th of April 2022.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial status"}}],"article-number":"788"}}